Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines.

Journal: Journal of autoimmunity

Volume: 122

Issue: 

Year of Publication: 2021

Affiliated Institutions:  Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA. Ulsan University College of Medicine, Seoul, Republic of Korea. Department of Data Science, Sejong University College of Software Convergence, Seoul, South Korea. Yonsei University College of Medicine, Seoul, Republic of Korea. Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain; ICREA, Pg. Lluis Companys , Barcelona, Spain. Parc Sanitari Sant Joan de Deu/CIBERSAM, Universitat de Barcelona, Fundacio Sant Joan de Deu, Sant Boi de Llobregat, Barcelona, Spain; Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain; Faculty of Medicine, University of Versailles Saint-Quentin-en-Yvelines, Montigny-le-Bretonneux, France. Laboratory of Microoranismes and Active Biomolecules, Sciences Faculty of Tunis, Tunis El Manar University, Tunis, Tunisia. Department of Pediatrics, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea. Electronic address: yonkkang@gmail.com. Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea. Electronic address: shinji@yuhs.ac. The Cambridge Centre for Sport and Exercise Sciences, Anglia Ruskin University, Cambridge, UK.

Abstract summary 

Cerebral venous thrombosis (CVT) events have been reported after vaccination with adenoviral COVID-19 vector vaccines. This study aimed to compare the clinical presentations and courses of vaccine-induced thrombotic thrombocytopenia (VITT) between the two adenoviral vector vaccines, Ad26.COV.2.S (Janssen/Johnson & Johnson) and ChAdOx1 nCoV-19 (Astra-Zeneca). We found that CVT after Ad26.COV.2.S vaccination presents later with similar symptoms compared to CVT after administration of ChAdOx1 nCoV-19, albeit with more thrombosis and intracerebral hemorrhage, lower D-dimer and aPTT levels but similar mortality. These findings could help guide clinical assessment and management of CVT after COVID-19 vaccination.

Authors & Co-authors:  Hwang Jimin J Lee Se Bee SB Lee Seung Won SW Lee Min Ho MH Koyanagi Ai A Jacob Louis L Tizaoui Kalthoum K Yon Dong Keon DK Shin Jae Il JI Smith Lee L

Study Outcome 

Source Link: Visit source

Statistics
Citations :  Greinacher A., Thiele T., Warkentin T.E., Weisser K., Kyrle P.A., Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N. Engl. J. Med. April 9, 2021 doi: 10.1056/NEJMoa2104840. Published online.
Authors :  10
Identifiers
Doi : 10.1016/j.jaut.2021.102681
SSN : 1095-9157
Study Population
Male,Female
Mesh Terms
Ad26COVS1
Other Terms
Adenoviral vector vaccine;COVID-19 vaccine;Cerebral venous thrombosis;Thrombotic thrombocytopenia syndrome;Vaccine-induced thrombotic thrombocytopenia
Study Design
Cross Sectional Study
Study Approach
Country of Study
Chad
Publication Country
England